TALIGEN THERAPEUTICS

taligen-therapeutics-logo

Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process.

#People #Financial #Event #Website #More

TALIGEN THERAPEUTICS

Industry:
Biotechnology Health Care Medical

Founded:
2004-01-01

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.taligentherapeutics.com

Total Employee:
11+

Status:
Closed

Contact:
617-444-8443

Email Addresses:
[email protected]

Total Funding:
78.75 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF LetsEncrypt Font Awesome Mobile Non Scaleable Content LiteSpeed Hetzner


Current Employees Featured

woodruff-emlen_image

Woodruff Emlen
Woodruff Emlen President and co-founder @ Taligen Therapeutics
President and co-founder

Founder


woodruff-emlen_image

Woodruff Emlen

Investors List

alta-partners_image

Alta Partners

Alta Partners investment in Series B - Taligen Therapeutics

sanderling-ventures_image

Sanderling Ventures

Sanderling Ventures investment in Series B - Taligen Therapeutics

clarus-ventures_image

Clarus Ventures

Clarus Ventures investment in Series B - Taligen Therapeutics

high-country-venture_image

High Country Venture

High Country Venture investment in Series B - Taligen Therapeutics

alta-partners_image

Alta Partners

Alta Partners investment in Series B - Taligen Therapeutics

clarus-ventures_image

Clarus Ventures

Clarus Ventures investment in Series B - Taligen Therapeutics

high-country-venture_image

High Country Venture

High Country Venture investment in Series B - Taligen Therapeutics

sanderling-ventures_image

Sanderling Ventures

Sanderling Ventures investment in Series B - Taligen Therapeutics

university-license-equity-holdings_image

University License Equity Holdings

University License Equity Holdings investment in Series A - Taligen Therapeutics

high-country-venture_image

High Country Venture

High Country Venture investment in Series A - Taligen Therapeutics

Key Employee Changes

Date New article
2024-09-26 Qualigen Therapeutics appoints Kevin Richardson as Interim CEO and CFO

Official Site Inspections

http://www.taligentherapeutics.com

Unable to get host informations!!!

Loading ...

More informations about "Taligen Therapeutics"

Taligen Therapeutics - Crunchbase Company Profile

Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement โ€ฆSee details»

Taligen Therapeutics Headquarters - StartUp Web Solutions

Headquarters 245 1st Street,Suite 1100,Cambridge, MA 02142 Type of Company Private Industries Pharmaceuticals Medical Support Services Company Description Taligen โ€ฆSee details»

Alexion Acquires Taligen Therapeutics and Creates Translational ...

Jan 31, 2011 Taligen's scientific staff will form the nucleus of Alexion's new Cambridge Massachusetts-based Translational Medicine Group, headed by Abbie Celniker, Ph.D., former โ€ฆSee details»

Taligen Therapeutics Inc., Woodruff Emlen,

[email protected]: Phone: 1-720-859-4056: Website: www.taligentherapeutics.com Fax: 1-720-859-4110: Summary ; Executive Details ; Board Members ; Business Information โ€ฆSee details»

Taligen Therapeutics - Company Profile - Tracxn

Taligen Therapeutics developed protein therapeutics for inflammatory diseases. Its therapies modulated the alternative pathway of the complement system to treat a wide range of โ€ฆSee details»

Taligen Therapeutics - Products, Competitors, Financials, โ€ฆ

Alexion Pharma Gobbles Up Taligen in $111M Buyout. Jan 31, 2011. XconomyBoston โ€” Thereโ€™s big news for Taligen Therapeutics this morning. Cheshire, CT-based Alexion Pharmaceuticals โ€ฆSee details»

Taligen Therapeutics - Headquarter Location, Corporate Office โ€ฆ

Taligen Therapeutics is Drug Discovery in United States that focus on Provider business. Founded in 2004. They cover business area such as Provider, development stage โ€ฆSee details»

Taligen Therapeutics 2025 Company Profile: Valuation, โ€ฆ

Taligen Therapeutics General Information Description. Provider of development stage biotechnology services for the treatment of inflammatory diseases. The company is developing therapies that regulate the complement system to treat โ€ฆSee details»

Nextsource | Company Profile | Taligen Therapeutics

Explore the company profile of Taligen Therapeutics (taligentherapeutics.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»

Alexion Pharmaceuticals Inc. Acquires Taligen Therapeutics

Jan 31, 2011 CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. announced that it has acquired Taligen Therapeutics, Inc., a privately held development-stage โ€ฆSee details»

Taligen Therapeutics - Ownership and Business Overview - Mergr

Taligen Therapeutics was founded in 2004. Life Science M&A Summary in 2011 Out of 60 sectors in the Mergr database, life science ranked 11 in number of deals in 2011 .See details»

Taligen Therapeutics - Contacts, Employees, Board Members, โ€ฆ

Taligen Therapeutics is focused on the R&D of novel protein therapeutics for the treatment of inflammatory conditions and diseases. New. Resources. Advanced Search. ... Log In. โ€ฆSee details»

Taligen Therapeutics - Crustdata Company Profile, Funding and โ€ฆ

Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of โ€ฆSee details»

Taligen Therapeutics Overview | SignalHire Company Profile

Organization Website: taligentherapeutics.com : Taligen Therapeutics industries Biotech: Taligen Therapeutics Employees Size 10-50 employees: Taligen Therapeutics headquarters is in โ€ฆSee details»

Taligen Therapeutics - VentureRadar

Acquired by Alexion Pharmaceuticals in January 2011 for $111 million. ... Find out more about Taligen Therapeutics, Biotech.See details»

CU licensee acquired by Alexion Pharma in buyout

Feb 8, 2011 Taligen Therapeutics, a licensee of the University of Colorado, was acquired recently by Cheshire, Conn.-based Alexion Pharmaceuticals for $111 million and contingent โ€ฆSee details»

Alexion Pads Biologic R&D with $111M Acquisition of Taligen

Jan 31, 2011 Company obtains preclinical-stage protein and antibody therapies. Alexion Pharmaceuticals acquired Taligen Therapeutics for $111 million, gaining preclinical-stage โ€ฆSee details»

Taligen Therapeutics - Funding, Financials, Valuation & Investors

Taligen Therapeutics is focused on the R&D of novel protein therapeutics for the treatment of inflammatory conditions and diseases. New. Resources. Advanced Search. ... How much โ€ฆSee details»

Taligen Therapeutics, Inc. - OpenGovCO

Taligen Therapeutics, Inc. (Entity# 19951070191) is a business corporation registered with Colorado Department of State (CDOS). The business formed date is May 30, 1995. ... Agent โ€ฆSee details»

Alexion snaps up Taligen for $111M-plus, creates translational unit

Jan 31, 2011 The promising protein drug developer Taligen Therapeutics is being snapped up by Alexion Pharmaceuticals for $111 million upfront and an undisclosed package of milestones โ€ฆSee details»

linkstock.net © 2022. All rights reserved